Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-13 |
2024-03 |
-0.6 |
-0.64 |
-0.04 |
-6.67% |
2024-03-05 |
2023-12 |
-0.45 |
N/A |
N/A |
N/A |
2024-03-05 |
2023-12 |
-0.45 |
-0.32 |
0.13 |
28.89% |
2023-11-13 |
2023-09 |
-0.38 |
N/A |
N/A |
N/A |
2023-11-13 |
2023-09 |
-0.38 |
-0.51 |
-0.13 |
-34.21% |
Date |
Firm |
Action |
From |
To |
2023-08-07 |
Guggenheim |
Upgrade |
|
Buy |
2023-08-07 |
Jefferies |
Upgrade |
|
Buy |
2023-08-07 |
Stifel |
Upgrade |
|
Buy |
2023-08-07 |
Wedbush |
Upgrade |
|
Outperform |
2023-08-07 |
TD Cowen |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2023-07-12 |
FAIRMOUNT FUNDS MANAGEMENT LLC |
Director |
0.00 |
Purchase |
2023-07-12 |
SHAH NIMISH P |
Director |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-09-29 |
SG Americas Securities, LLC |
4.93K |
105.03K |
0.01% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-07-30 |
Franklin Strategic Series-Franklin Small Cap Growth Fund |
446.80K |
9.56M |
0.88% |
2023-07-30 |
Fidelity Blue Chip Growth Fund |
278.50K |
5.96M |
0.55% |
2023-08-30 |
Fidelity Growth Company Fund |
279.51K |
6.41M |
0.55% |
2023-08-30 |
Fidelity Select Portfolios - Biotechnology |
265.36K |
6.09M |
0.52% |
2023-07-30 |
Fidelity Advisor Biotechnology Fund |
141.80K |
3.03M |
0.28% |
2023-07-30 |
Franklin Strategic Series-Franklin Biotechnology Discove |
139.82K |
2.99M |
0.28% |